BE assessment regarding first time point Cmax [Study Assessment]
Hello Erkin,
The whole business of dropping certain subjects, disregarding data, and getting rid of some data data while keeping other data is a discipline in which many companies, CROs and applicants are extremely skilled but not overly successful when facing regulators. If the guideline does not mention the opportunity to drop subjects data in accordance with your decision scheme then perhaps that is because regulators don't want you to drop data that way? Just thinking of this as a remote hypothetical possibility.
Funnily enough, perhaps it is just me hallucinating: Sometimes I get the impression that when CROs and Sponsors try and enter these discussions about getting rid of certain data in ways not stipulated by a protocol it seems always to be about getting rid of data that is unwanted for the purpose of showing BE, and much effort is put into keeping just the data the result in demonstration of BE. Isn't that really, really strange....?
❝ If these early samples were not collected, then those subjects with first point Cmax values should be dropped from the primary statistical analysis.
❝
❝ I couldn't find the reference from EMA or FDA about dropping the subjects. I've contacted to Dr. Leon Shargel via e-mail and asked him the same question.
The whole business of dropping certain subjects, disregarding data, and getting rid of some data data while keeping other data is a discipline in which many companies, CROs and applicants are extremely skilled but not overly successful when facing regulators. If the guideline does not mention the opportunity to drop subjects data in accordance with your decision scheme then perhaps that is because regulators don't want you to drop data that way? Just thinking of this as a remote hypothetical possibility.
Funnily enough, perhaps it is just me hallucinating: Sometimes I get the impression that when CROs and Sponsors try and enter these discussions about getting rid of certain data in ways not stipulated by a protocol it seems always to be about getting rid of data that is unwanted for the purpose of showing BE, and much effort is put into keeping just the data the result in demonstration of BE. Isn't that really, really strange....?
—
Pass or fail!
ElMaestro
Pass or fail!
ElMaestro
Complete thread:
- BE assessment regarding first time point Cmax Mann 2018-12-09 10:14 [Study Assessment]
- BE assessment regarding first time point Cmax Ohlbe 2018-12-09 23:46
- BE assessment regarding first time point Cmax Mann 2018-12-10 00:28
- BE assessment regarding first time point Cmax Ohlbe 2018-12-11 00:05
- FDA and outliers mittyri 2018-12-11 16:38
- BE assessment regarding first time point Cmax Erkin 2018-12-28 08:29
- BE assessment regarding first time point CmaxElMaestro 2018-12-28 14:32
- BE assessment regarding first time point Cmax Erkin 2018-12-28 20:57
- regulatory reasons to consider the study inadequate Astea 2019-03-02 18:02
- Good question, next question Helmut 2019-03-03 19:42
- first point Cmax: trouble waiting to happen? Astea 2019-03-03 21:42
- Good question, next question Helmut 2019-03-03 19:42
- regulatory reasons to consider the study inadequate Astea 2019-03-02 18:02
- BE assessment regarding first time point Cmax Erkin 2018-12-28 20:57
- BE assessment regarding first time point CmaxElMaestro 2018-12-28 14:32
- BE assessment regarding first time point Cmax Mann 2018-12-10 00:28
- BE assessment regarding first time point Cmax Ohlbe 2018-12-09 23:46